To Verify the Efficacy and Safety of Rapamycin Coated Peripheral Balloon Catheter in the Treatment of Femoral Popliteal Artery Disease

Inclusion Criteria: * Patients with arteriosclerosis obliterans of lower extremities, and Rutherford's rating is 2-5. * Patients with severe stenosis (≥ 70%) or occlusion of superficial femoral artery and/or proximal popliteal artery (within P1 stage) * Patients with total length of target lesion ≤ 20cm and length of occluded segment ≤ 15cm (the distance between two segments of lesions less than 2cm is considered as the same lesion) * Those who agree to participate in this clinical trial and sign the informed consent form Exclusion criteria： * This operation is planned to intervene patients with bilateral lower limbs. * Patients whose guide wire fails to pass through the target lesion. * Patients whose target lesion is in stent restenosis (ISR). * ≥ 2 lesions need to be treated in the target vessel (if the distance between two lesions is less than 2cm, it is considered as the same lesion). * Patients with target lesions requiring rotary resection/laser therapy/thrombus aspiration for this treatment. * Patients with ipsilateral iliac artery inflow tract lesions that cannot be successfully treated (i.e. residual stenosis ≥ 30% after treatment). * There is less than one unobstructed blood vessel under the knee of the target limb before operation (unobstructed is defined as visual stenosis\<50%). * Residual stenosis ≥ 30% after pre expansion of target lesion or severe (≥ Grade D) flow limiting dissection. * Patients with obviously abnormal renal function (creatinine \> 2.5mg/dL or 220umol/L) or undergoing dialysis. * Patients with severe liver dysfunction who are judged by the researcher to be unsuitable for surgery. * Patients with severe coagulation dysfunction or uncontrolled severe infection who are not suitable for surgery. * Patients who have performed distal amputation (above metatarsal) on the affected or opposite limb in the past. * Patients who received local or systemic thrombolytic therapy within 48 hours before surgery. * Patients receiving vascular interventional therapy or surgical treatment on target limb within 30 days before operation. * Patients known to be allergic to aspirin, clopidogrel, paclitaxel and rapamycin. * Pregnant or lactating women and patients with family planning during the study * Patients who are participating in clinical trials of other drugs or medical devices but are not included in the group. * Patients with life expectancy less than 12 months * Patients not suitable for this study.